We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

50 hedge funds and large institutions have $26M invested in AYTU BioPharma in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more call options, than puts

Call options by funds: $1.37M | Put options by funds: $808K

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

0.33% less ownership

Funds ownership: 1.36% → 1.03% (-0.33%)

22% less funds holding

Funds holding: 64 → 50 (-14)

46% less capital invested

Capital invested by funds: $48.4M → $26M (-$22.4M)

58% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 24

Holders
50
Holders Change
-14
Holders Change %
-21.88%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
15
Reduced
15
Closed
24
Calls
$1.37M
Puts
$808K
Net Calls
+$566K
Net Calls Change
+$350K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.58M
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.03M
3
VF
Virtu Financial
New York
+$597K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$563K
5
E
Ergoteles
New York
+$443K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$6.48M
2
SCM
Stonepine Capital Management
Oregon
-$2.76M
3
Nuveen
Nuveen
North Carolina
-$2.1M
4
Northern Trust
Northern Trust
Illinois
-$974K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$822K

AYTU Hedge Fund Activity: Q2 2021 in Review

50 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2021, worth a combined $26M — down 46% from $48.4M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of AYTU and 10 opened new positions — a net loss of 14 holders — while 15 trimmed existing stakes and 15 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $2.58M. The largest seller was BlackRock, cutting an estimated $6.48M.

  • 50 institutional investors held AYTU BioPharma (AYTU) as of Q2 2021, down from 64 in Q1 2021.
  • Funds reported $26M of AYTU BioPharma stock for Q2 2021, down 46% quarter-over-quarter.
  • 10 funds opened new AYTU BioPharma positions in Q2 2021 and 24 closed out, a net change of -14 holders.
  • The largest AYTU BioPharma buyer in Q2 2021 was Millennium Management, an estimated $2.58M added.
  • The largest AYTU BioPharma seller in Q2 2021 was BlackRock, an estimated $6.48M sold.

Based on aggregated 13F filings for Q2 2021.